Literature DB >> 2920955

Ovarian clear cell adenocarcinoma.

A W Kennedy1, C V Biscotti, W R Hart, K D Webster.   

Abstract

The clinical and pathologic features of 29 cases of ovarian clear cell adenocarcinoma (OCCA) were studied to evaluate outcome and potential predictors of survival. Patients' ages ranged from 30 to 89 years (median, 54 years). The study group, using the FIGO classification, consisted of 10 Stage I, 5 Stage II, 7 Stage III, 5 Stage IV, and 2 unstaged patients. Previous or concurrent endometriosis was noted in 45% of patients. Three patients (10.3%) had hypercalcemia. Only stage and the presence of macroscopic residual disease had a statistically significant association with survival. Stage I and II patients experienced a survival similar to a group of 305 patients with adenocarcinomas of non-clear cell type in our ovarian cancer registry with the exception of the very poor survival among Stage IC OCCA patients. Patients with Stage III and IV OCCA had a worse survival than non-OCCA registry patients of similar stage. Few objective responses to adjuvant chemotherapy could be demonstrated in these high-stage OCCA patients. Further study of postoperative adjuvant therapies is warranted.

Entities:  

Mesh:

Year:  1989        PMID: 2920955     DOI: 10.1016/0090-8258(89)90637-9

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  31 in total

1.  MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Authors:  Chandra Bartholomeusz; Tetsuro Oishi; Hitomi Saso; Ugur Akar; Ping Liu; Kimie Kondo; Anna Kazansky; Savitri Krishnamurthy; Jangsoon Lee; Francisco J Esteva; Junzo Kigawa; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2011-12-05       Impact factor: 6.261

Review 2.  Ovarian clear cell adenocarcinoma: a continuing enigma.

Authors:  David S P Tan; Stan Kaye
Journal:  J Clin Pathol       Date:  2006-10-03       Impact factor: 3.411

3.  Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.

Authors:  Emily N Prendergast; Marie Holzapfel; Jennifer J Mueller; Mario M Leitao; Camille C Gunderson; Kathleen N Moore; Britt K Erickson; Charles A Leath; Elena S Diaz Moore; Joshua G Cohen; Christine S Walsh
Journal:  Gynecol Oncol       Date:  2016-12-12       Impact factor: 5.482

Review 4.  Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.

Authors:  Daichi Maeda; Ie-Ming Shih
Journal:  Adv Anat Pathol       Date:  2013-01       Impact factor: 3.875

5.  Nonbacterial thrombotic endocarditis with recurrent embolic events as manifestation of ovarian neoplasm.

Authors:  Arash Aryana; Dennis J Esterbrooks; Peter C Morris
Journal:  J Gen Intern Med       Date:  2006-09-11       Impact factor: 5.128

6.  Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.

Authors:  William J Lowery; Joellen M Schildkraut; Liudmila Akushevich; Rex Bentley; Jeffrey R Marks; David Huntsman; Andrew Berchuck
Journal:  Int J Gynecol Cancer       Date:  2012-01       Impact factor: 3.437

7.  The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review).

Authors:  Hiroshi Shigetomi; Akira Oonogi; Taihei Tsunemi; Yasuhito Tanase; Yoshihiko Yamada; Hirotaka Kajihara; Yoriko Yoshizawa; Naoto Furukawa; Shoji Haruta; Shozo Yoshida; Toshiyuki Sado; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2011-05-16       Impact factor: 2.967

8.  A novel human monoclonal antibody against cervical cancer: its immunoreactivity with normal tube and ovary and with ovarian tumor tissue.

Authors:  T Nakanishi; T Okamoto; A Nawa; T Suzuki; K Ino; Y Wakahara; N Horibe; S Goto; Y Tomoda
Journal:  Arch Gynecol Obstet       Date:  1995       Impact factor: 2.344

9.  Napsin A is a specific marker for ovarian clear cell adenocarcinoma.

Authors:  Yoriko Yamashita; Tetsuro Nagasaka; Aya Naiki-Ito; Shinya Sato; Shugo Suzuki; Shinya Toyokuni; Masafumi Ito; Satoru Takahashi
Journal:  Mod Pathol       Date:  2014-04-11       Impact factor: 7.842

10.  Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer.

Authors:  Peng Liu; Ashwani Khurana; Ramandeep Rattan; Xiaoping He; Steve Kalloger; Sean Dowdy; Blake Gilks; Viji Shridhar
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.